Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer

[1] Marotta LL(2011)The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(−) stem cell-like breast cancer cells in human tumors J Clin Invest 121 2723-2735

[2] Almendro V(2008)The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype Am J Pathol 173 561-574

[3] Marusyk A(2012)JAK2/STAT3 activity in inflammatory breast cancer supports the investigation of JAK2 therapeutic targeting Cancer Res 72 24-2407

[4] Shipitsin M(2018)Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer NPJ Breast Cancer 4 10-4047

[5] Schemme J(2018)A phase Ib study of ruxolitinib + gemcitabine +/− nab-paclitaxel in patients with advanced solid tumors Onco Targets Ther 11 2399-798

[6] Walker SR(2015)Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed J Clin Oncol 33 4039-807

[7] Bloushtain-Qimron N(2012)JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 787-1810

[8] Kim JJ(2012)A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 799-24319

[9] Choudhury SA(2020)Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease N Engl J Med 382 1800-3217

[10] Maruyama R(2018)Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer Oncotarget 9 24304-4217

[1] Marotta LL(2011)The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(−) stem cell-like breast cancer cells in human tumors J Clin Invest 121 2723-2735

[2] Almendro V(2008)The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype Am J Pathol 173 561-574

[3] Marusyk A(2012)JAK2/STAT3 activity in inflammatory breast cancer supports the investigation of JAK2 therapeutic targeting Cancer Res 72 24-2407

[4] Shipitsin M(2018)Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer NPJ Breast Cancer 4 10-4047

[5] Schemme J(2018)A phase Ib study of ruxolitinib + gemcitabine +/− nab-paclitaxel in patients with advanced solid tumors Onco Targets Ther 11 2399-798

[6] Walker SR(2015)Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed J Clin Oncol 33 4039-807

[7] Bloushtain-Qimron N(2012)JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 787-1810

[8] Kim JJ(2012)A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 799-24319

[9] Choudhury SA(2020)Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease N Engl J Med 382 1800-3217

[10] Maruyama R(2018)Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer Oncotarget 9 24304-4217